by Paul Krzyzanowski | May 22, 2012
Many readers may already have heard of Health Canada’s approval of Osiris’ Prochymal, a mesenchymal stem cell treatment for severe cases of pediatric Graft versus Host Disease (GvHD), with plenty of coverage circulating around the web. GvHD is a disease where...
by Paul Krzyzanowski | May 4, 2012
Commercialization plenary summary: part 3 of 4 On day two (May 1) of the Till and McCulloch Meetings, Dr. Emily Culme-Seymour from the London Regenerative Medicine Network introduced work that leverages previous clinical trial information to support future cell...
by David Kent | Sep 30, 2010
Last week, a major kerfuffle erupted in the UK stem cell community as leading scientists and pro stem cell organizations argued that Britain’s range of economic austerity measures would jeopardize their ability to be a major player in translational research. Articles...
Comments